Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 2 (February)

1. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
   Cancer Res, 66(3): 1640-7. [Abstract] [Full-text]
2. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
   Cancer Res, 66(3): 1630-9. [Abstract] [Full-text]
3. Herceptin: mechanisms of action and resistance.
   Cancer Lett, 232(2): 123-38. [Abstract] [Full-text]
4. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
   Ann Pharmacother, 40(2): 261-9. [Abstract] [Full-text]
5. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.
   Am J Clin Oncol, 29(1): 90-5. [Abstract] [Full-text]
6. The burden of scientific progress: Growing inequalities in the delivery of cancer care.
   Acta Oncol, 45(1): 84-6. [Abstract] [Full-text]
7. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
   Clin Cancer Res, 12(3): 904-16. [Abstract] [Full-text]
8. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
   Clin Cancer Res, 12(3): 845-53. [Abstract] [Full-text]
9. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder.
   J Urol, 175(3): 875-80; discussion 880. [Abstract] [Full-text]
10. Anticancer agents and cardiotoxicity.
    Semin Oncol, 33(1): 2-14. [Abstract] [Full-text]
11. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial.
    Cancer Chemother Pharmacol, 57(5): 554-8. [Abstract] [Full-text]
12. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
    Oncologist, 11(2): 111-25. [Abstract] [Full-text]
13. Targeting insulin-like growth factor pathways.
    Br J Cancer, 94(4): 465-8. [Abstract] [Full-text]
14. Locally advanced breast cancer.
    Curr Opin Obstet Gynecol, 18(1): 47-52. [Abstract] [Full-text]
15. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    N Engl J Med, 354(8): 809-20. [Abstract] [Full-text]
16. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
    Ann Oncol, 17(3): 409-14. [Abstract] [Full-text]
17. An economic evaluation of Herceptin(R) in adjuvant setting: the Breast Cancer International Research Group 006 trial.
    Ann Oncol, 17(3): 381-90. [Abstract] [Full-text]
18. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
    Expert Rev Anticancer Ther, 6(3): 427-36. [Abstract] [Full-text]
19. Molecular targeted therapy: a strategy of disillusions or optimism?
    J Lab Clin Med, 147(3): 108-13. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.